Spyre Therapeutics News

Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors

ReutersJul 18 08:00 ET

Express News | Spyre Therapeutics Shares up 6.1% After Evercore ISI Initiates Coverage With Outperform Rating

ReutersJul 16 09:40 ET

Express News | Spyre Therapeutics Inc : Evercore ISI Initiates Coverage With Outperform Rating

ReutersJul 16 08:00 ET

Evercore Initiates Spyre Therapeutics(SYRE.US) With Buy Rating

Moomoo NewsJul 16 07:31 ET · Ratings

Express News | Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024

ReutersJun 18 07:34 ET

Express News | Spyre to Present Interim Spy001 Data by Year-End 2024

ReutersJun 18 07:33 ET

Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease

ReutersJun 18 07:30 ET

Spyre Therapeutics Down Nearly 20%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk

Dow JonesJun 17 14:23 ET

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

moomoo NewsJun 13 16:33 ET · Ratings

Spyre Therapeutics Announces Grants of Inducement Awards

PR NewswireJun 3 17:23 ET

Spyre Therapeutics Announces Updated Share Structure

TipRanksMay 30 17:27 ET

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

PR NewswireMay 29 08:30 ET

On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K

BenzingaMay 15 07:56 ET

Spyre Therapeutics Expands Portfolio and Strengthens Leadership

TipRanksMay 15 07:52 ET

Express News | Spyre Therapeutics Appoints Accomplished Biopharma Leader DR. Sandra Milligan to Its Board of Directors

ReutersMay 15 07:30 ET

Positive Outlook on Spyre Therapeutics' IBD Pipeline and Financial Stability

TipRanksMay 14 04:48 ET

Spyre Therapeutics Is Maintained at Overweight by Wells Fargo

Dow JonesMay 13 09:55 ET

Express News | Spyre Therapeutics, Inc. : Wells Fargo Raises Target Price to $40 From $35

ReutersMay 13 07:11 ET

Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook

TipRanksMay 10 12:45 ET

Spyre Therapeutics Is Maintained at Buy by BTIG

Dow JonesMay 10 11:03 ET